
Glioma drug combo turns tumours hot
Swiss researchers have shrinked one of the most lethal and untreatable types of cancer in mice using a combination treatment that proved safe in five...

Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd’s exclusive license deal with VYNE Therapeutics Inc. on the oral BET inhibitor, TAY-B2 (now known as VYN201) forsees an upfront...

Ariceum Therapeutics extends Series A to €47.75m
The Series A financing was co-led by new investors Andera Partners and Earlybird Venture Capital. Existing investor Pureos Bioventures doubled its...

Wacker AG expands biotech business through €100m acquisition
Following Wacker’s purchase of fermentation assets in the northern Spanish city of León in 2016, the chemical group now owns the entire site. The...

Medigene licences CD40L-CD28 costimulatory switch receptor
Medigene has licences the global exclusive rights for CD40L-CD28 costimulatory switch receptor from the Helmholtz Centre Munich. Financial details...

Forbion raises €1.35bn across two funds
Both funds, the early stage Forbion Ventures Fund VI (€750m) and the Forbion Growth Opportunities Fund II (€600m), which will invest up to €70m in up...

Roche’s meets endpoints in relapsing multiple sclerosis
In patients with relapsing-remitting multiple sclerosis (RRMS), fenebrutinib significantly reduced the total number of new gadolinium-enhancing...